2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
How testing the gut could help in the early detection of Parkinson’s
Recent results from a Cure Parkinson’s funded study have provided more evidence for a possible role of the gut in Parkinson’s, as well as identifying new markers to aid in early detection of the condition. There is growing evidence to suggest that the gut may…
Insights on grant applications and research funding from our latest Research Committee interns
At the end of 2023, Cure Parkinson’s set up an internship scheme for PhD students or early post-doctoral researchers to join our Research Committee for a one-year period. This committee is responsible for rigorously reviewing each of our funding applications to ensure they are scientifically robust…
October Walking Challenge raises over £63k for Cure Parkinson’s
Our amazing supporters challenged themselves to walk 100km throughout the month of October to raise vital funds for Parkinson’s research. Over the past couple of years we’ve organised virtual walking challenges on Facebook to unite new and existing supporters across the UK and beyond. This…
Cure Parkinson’s Fundraising Heroes: October 2024
In October, many of Cure Parkinson’s fundraising heroes laced up their trainers to run in support of our research. But running wasn’t the only challenge our fundraisers got up to, with one supporter organising a charity concert too! Run to the Sea Bournemouth Brothers Gavin…
Our latest pre-clinical research project: evaluating the neuroprotective properties of ‘CP-6’
Cure Parkinson’s is excited to announce funding for a new pre-clinical study of ‘CP-6’ for Parkinson’s led by Dr Marco Fazzari and his team at the University of Pittsburgh. CP-6 is a new drug being developed by Creegh Pharmaceuticals. Early lab-based studies have suggested that…